(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.
The three biggest winners today are CLARANOVA, LAVIDE HOLDING, and DISTRI-LAND CERT.
| Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|
| CLARANOVA (CLA.PA) | 2.96 | 15.88% | 2024-02-12 13:01:13 |
| LAVIDE HOLDING (LVIDE.AS) | 0.28 | 10.32% | 2024-02-12 12:02:47 |
| DISTRI-LAND CERT (DISL.BR) | 254.00 | 9.48% | 2024-02-12 12:05:51 |
| TEKNA HOLDING (TEKNA.OL) | 8.38 | 8.83% | 2024-02-12 12:43:53 |
| ELECTROMAGNET GEO (EMGS.OL) | 2.71 | 8.4% | 2024-02-12 12:25:46 |
| GENFIT (GNFT.PA) | 3.72 | 8.3% | 2024-02-12 13:04:14 |
| ONWARD MEDICAL (ONWD.BR) | 5.92 | 7.64% | 2024-02-12 12:21:00 |
| ESSO (ES.PA) | 62.35 | 7.59% | 2024-02-12 13:02:49 |
| VIVORYON (VVY.AS) | 9.75 | 7.03% | 2024-02-12 12:04:30 |
| GUERBET (GBT.PA) | 27.50 | 7% | 2024-02-12 13:04:42 |
The three biggest losers today are MITHRA, STRONGPOINT, and FORSEE POWER.
| Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|
| MITHRA (MITRA.BR) | 0.54 | -9.83% | 2024-02-12 12:20:44 |
| STRONGPOINT (STRO.OL) | 13.75 | -8.33% | 2024-02-12 12:43:46 |
| FORSEE POWER (FORSE.PA) | 2.35 | -6.37% | 2024-02-12 13:03:56 |
| CELYAD ONCOLOGY (CYAD.BR) | 0.37 | -5.85% | 2024-02-12 12:05:29 |
| VAA VISTA ALEGRE (VAF.LS) | 0.91 | -5.73% | 2024-02-12 12:24:06 |
| KEYWARE TECH. (KEYW.BR) | 0.94 | -5.05% | 2024-02-12 12:20:33 |
| AKVA GROUP (AKVA.OL) | 49.20 | -5.02% | 2024-02-12 12:24:34 |
| HOFSETH BIOCARE (HBC.OL) | 2.30 | -4.96% | 2024-02-12 12:40:29 |
| TELEVERBIER (TVRB.PA) | 54.50 | -4.39% | 2024-02-12 13:23:36 |
| HYBRID SOFTWARE GR (HYSG.BR) | 3.14 | -4.27% | 2024-02-12 12:20:10 |
Winners today
1. CLARANOVA (CLA.PA)
15.88% Price Change
Claranova SE, a technology company, engages in personalized e-commerce, software publishing, and internet of things (IoT) management in France, the United States, the United Kingdom, Germany, other European countries, and internationally. It operates in three segments: PlanetArt, Avanquest, and myDevices. The PlanetArt segment offers photos, frames, personalized books, and FreePrints mobile applications. The Avanquest segment provides antivirus, ad blocker, cleaning, and optimization tools under the Adaware brand; document management tools under the SodaPDF brand; and photo editor software and applications developed under the inPixio brand. The myDevices segment offers IoT solutions. Claranova SE was incorporated in 1984 and is headquartered in Courbevoie, France.
CAC 40 ended the session with CLARANOVA rising 15.88% to €2.96 on Monday while CAC 40 jumped 0.55% to €7,689.80.
Earnings Per Share
As for profitability, CLARANOVA has a trailing twelve months EPS of €-0.23.
More news about CLARANOVA.
2. LAVIDE HOLDING (LVIDE.AS)
10.32% Price Change
Lavide Holding N.V. does not have significant operations. Previously, it was engaged in the provision of integrated information technology solutions for medium to large-sized companies and organizations. The company was formerly known as Qurius N.V. and changed its name to Lavide Holding N.V. in July 2013. Lavide Holding N.V. is based in Amsterdam, the Netherlands.
AEX-Index ended the session with LAVIDE HOLDING jumping 10.32% to €0.28 on Monday while AEX-Index jumped 0.37% to €854.88.
Earnings Per Share
As for profitability, LAVIDE HOLDING has a trailing twelve months EPS of €-0.02.
Yearly Top and Bottom Value
LAVIDE HOLDING’s stock is valued at €0.28 at 21:40 EST, way under its 52-week low of €0.18.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, LAVIDE HOLDING’s stock is considered to be overbought (>=80).
Volatility
LAVIDE HOLDING’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.86%, a negative 1.19%, and a positive 5.65%.
LAVIDE HOLDING’s highest amplitude of average volatility was 4.28% (last week), 5.59% (last month), and 5.65% (last quarter).
More news about LAVIDE HOLDING.
3. DISTRI-LAND CERT (DISL.BR)
9.48% Price Change
Immobiliere Distri-Land NV engages in the issuance of real estate certificates. The company is based in Molenbeek-Saint-Jean, Belgium. Immobiliere Distri-Land NV operates as a subsidiary of KBC Bank NV.
BEL 20 ended the session with DISTRI-LAND CERT jumping 9.48% to €254.00 on Monday while BEL 20 jumped 1.07% to €3,715.85.
Earnings Per Share
As for profitability, DISTRI-LAND CERT has a trailing twelve months EPS of €7.54.
PE Ratio
DISTRI-LAND CERT has a trailing twelve months price to earnings ratio of 33.69. Meaning, the purchaser of the share is investing €33.69 for every euro of annual earnings.
Volume
Today’s last reported volume for DISTRI-LAND CERT is 19 which is 533.33% above its average volume of 3.
More news about DISTRI-LAND CERT.
4. TEKNA HOLDING (TEKNA.OL)
8.83% Price Change
Tekna Holding ASA develops, manufactures, and sells micro and nano powders, and plasma process solutions in North America, Europe, Asia, and internationally. The company offers spherical powders, such as titanium, nickel, and aluminum alloys, as well as tungsten and tantalum; and nanopowders, including nickel nanopowder, silicon nanopowder, copper nanopowder, and boron nitride nanotubes for use in additive manufacturing, metal injection molding, thermal spray, and hot isostatic pressing. It serves aviation, aerospace, medical, mining and drilling, energy storage, and microelectronics industries. The company was founded in 1990 and is headquartered in Sherbrooke, Canada. Tekna Holding ASA is a subsidiary of Arendals Fossekompani ASA.
Oslo Børs Benchmark Index_GI ended the session with TEKNA HOLDING jumping 8.83% to €8.38 on Monday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI rose 0.84% to €1,250.87, following the last session’s upward trend on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, TEKNA HOLDING has a trailing twelve months EPS of kr-0.87.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -26.89%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 53.5%, now sitting on 36.34M for the twelve trailing months.
Yearly Top and Bottom Value
TEKNA HOLDING’s stock is valued at kr8.38 at 21:40 EST, way under its 52-week high of kr11.25 and way above its 52-week low of kr5.30.
Sales Growth
TEKNA HOLDING’s sales growth is 11.5% for the present quarter and 62% for the next.
More news about TEKNA HOLDING.
5. ELECTROMAGNET GEO (EMGS.OL)
8.4% Price Change
Electromagnetic Geoservices ASA, together with its subsidiaries, provides electromagnetic (EM) surveying services to the offshore oil and gas exploration industry. It is involved in the planning, acquisition, processing, modelling, interpretation, and integration of EM data. The company uses its patented EM survey method to find hydrocarbons in offshore reservoirs. It engages in the provision of controlled-source EM surveying and magneto telluric surveying; imaging and interpretation; rental of software and cluster; and training services. The company has operations in Europe, the Middle East, Africa, Norway, North and South America, Asia, and the Pacific Ocean. Electromagnetic Geoservices ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with ELECTROMAGNET GEO jumping 8.4% to €2.71 on Monday while Oslo Børs Benchmark Index_GI rose 0.84% to €1,250.87.
Earnings Per Share
As for profitability, ELECTROMAGNET GEO has a trailing twelve months EPS of kr0.32.
PE Ratio
ELECTROMAGNET GEO has a trailing twelve months price to earnings ratio of 8.47. Meaning, the purchaser of the share is investing kr8.47 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 145.52%.
More news about ELECTROMAGNET GEO.
6. GENFIT (GNFT.PA)
8.3% Price Change
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
CAC 40 ended the session with GENFIT rising 8.3% to €3.72 on Monday, following the last session’s downward trend. CAC 40 rose 0.55% to €7,689.80, following the last session’s downward trend on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, GENFIT has a trailing twelve months EPS of €-0.75.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -37.21%.
Volume
Today’s last reported volume for GENFIT is 249680 which is 10.53% below its average volume of 279096.
More news about GENFIT.
7. ONWARD MEDICAL (ONWD.BR)
7.64% Price Change
Onward Medical N.V., a medical technology company, focuses on developing therapies for spinal cord injuries in the Netherlands and internationally. The company engages in developing ARC-EX, an external non-invasive platform that consists of a wearable stimulator and wireless programmer; and ARCIM, an implantable platform, which consists of an implantable pulse generator and lead that is placed near the spinal cord. It also engages in developing Up-LIFT Trial to evaluate the safety and effectiveness of non-invasive electrical spinal cord stimulation to treat upper extremity functional deficits with chronic tetraplegia. The company was founded in 2014 and is headquartered in Eindhoven, Netherlands.
BEL 20 ended the session with ONWARD MEDICAL rising 7.64% to €5.92 on Monday while BEL 20 rose 1.07% to €3,715.85.
Earnings Per Share
As for profitability, ONWARD MEDICAL has a trailing twelve months EPS of €-1.2.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -69.93%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 3.6%, now sitting on 2.11M for the twelve trailing months.
Yearly Top and Bottom Value
ONWARD MEDICAL’s stock is valued at €5.92 at 21:40 EST, below its 52-week high of €6.34 and way higher than its 52-week low of €1.85.
More news about ONWARD MEDICAL.
8. ESSO (ES.PA)
7.59% Price Change
Esso S.A.F. refines, distributes, and markets refined petroleum products in France and internationally. It offers gas, gasoline, kerosene, diesel, and heavy fuel oil; and base oils, finished lubricants, white oils, paraffins, and bitumens. The company also manufactures and sells finished lubricants and greases; and wholesales fuel oil, diesel, non-road diesel, and fuels. In addition, it operates a network of service stations under the Esso and Esso Express brands. The company offers fuels under the Esso brand name and lubricants under the Mobil brand. It markets its products through a network of distributors and resellers, as well as directly to customers. The company was incorporated in 1900 and is headquartered in Nanterre, France. Esso S.A.F. operates as a subsidiary of ExxonMobil France Holding S.A.S.
CAC 40 ended the session with ESSO jumping 7.59% to €62.35 on Monday while CAC 40 jumped 0.55% to €7,689.80.
Earnings Per Share
As for profitability, ESSO has a trailing twelve months EPS of €-6.99.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.52%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jul 10, 2023, the estimated forward annual dividend rate is 2 and the estimated forward annual dividend yield is 3.45%.
Yearly Top and Bottom Value
ESSO’s stock is valued at €62.35 at 21:40 EST, under its 52-week high of €63.90 and way higher than its 52-week low of €41.06.
Revenue Growth
Year-on-year quarterly revenue growth declined by 22.8%, now sitting on 22.19B for the twelve trailing months.
Volatility
ESSO’s last week, last month’s, and last quarter’s current intraday variation average was 1.49%, 0.58%, and 1.50%.
ESSO’s highest amplitude of average volatility was 2.03% (last week), 1.71% (last month), and 1.50% (last quarter).
More news about ESSO.
9. VIVORYON (VVY.AS)
7.03% Price Change
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.
AEX-Index ended the session with VIVORYON rising 7.03% to €9.75 on Monday while AEX-Index rose 0.37% to €854.88.
Earnings Per Share
As for profitability, VIVORYON has a trailing twelve months EPS of €-1.12.
Volume
Today’s last reported volume for VIVORYON is 171221 which is 147.99% above its average volume of 69041.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, VIVORYON’s stock is considered to be oversold (<=20).
More news about VIVORYON.
10. GUERBET (GBT.PA)
7% Price Change
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services. In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and SeQure and DraKon, which are microcatheters. Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. The company was incorporated in 1926 and is headquartered in Villepinte, France.
CAC 40 ended the session with GUERBET rising 7% to €27.50 on Monday, after two sequential sessions in a row of gains. CAC 40 rose 0.55% to €7,689.80, following the last session’s downward trend on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, GUERBET has a trailing twelve months EPS of €-3.35.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -10.79%.
More news about GUERBET.
Losers Today
1. MITHRA (MITRA.BR)
-9.83% Price Change
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.
BEL 20 ended the session with MITHRA sliding 9.83% to €0.54 on Monday, following the last session’s downward trend. BEL 20 rose 1.07% to €3,715.85, after three sequential sessions in a row of gains, on what was an all-around positive trend trading session today.
Earnings Per Share
As for profitability, MITHRA has a trailing twelve months EPS of €-1.41.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -575.59%.
Moving Average
MITHRA’s value is way below its 50-day moving average of €1.16 and way below its 200-day moving average of €1.79.
More news about MITHRA.
2. STRONGPOINT (STRO.OL)
-8.33% Price Change
StrongPoint ASA engages in the development, sale, and implementation of integrated technology solutions for stores and e-commerce operations in Norway, Sweden, and internationally. It offers various products and solutions comprising electronic shelf labels, scales and wrapping systems, and grocery robots; order and in-store picking, home delivery, grocery lockers, drive-through, and autostore microfulfilment solutions; cash management systems; and shop fitting services, as well as other retail technology and self-checkout solutions. The company also provides ShopFlow Logistics, a cloud based mobile logistics system for handling routines that include receiving goods, inventory, balance adjustment, ordering labels printing, and waste management; and Vensafe, which automates in-store sales of restricted and theft-prone products. It has a strategic partnership with Halodi Robotics to develop robotic solutions for the grocery retail sector. The company was formerly known as PSI Group ASA and changed its name to StrongPoint ASA in September 2015. StrongPoint ASA was incorporated in 2000 and is headquartered in Rælingen, Norway.
Oslo Børs Benchmark Index_GI ended the session with STRONGPOINT falling 8.33% to €13.75 on Monday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI rose 0.84% to €1,250.87, following the last session’s upward trend on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, STRONGPOINT has a trailing twelve months EPS of kr0.14.
PE Ratio
STRONGPOINT has a trailing twelve months price to earnings ratio of 98.21. Meaning, the purchaser of the share is investing kr98.21 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.51%.
More news about STRONGPOINT.
3. FORSEE POWER (FORSE.PA)
-6.37% Price Change
Forsee Power Société anonyme, together with its subsidiaries, engages in the design, manufacture, assemble, and supply of lithium-based battery systems for mobility applications in France, Europe, Asia, the United States, and internationally. It operates in two segments: Heavy Vehicles, and Light Vehicles and Industrial Tech. The company's products are used in the field of autonomy and mobility for applications in bicycles, scooters, rolling stock, medical facilities, home automation, professional tools, etc.; electric transport for applications in buses, trucks, trams, shipping and rail transport, and marine and offshore vessels; and storage of electrical energy for residential, commercial, and industrial market applications. The company was incorporated in 2007 and is headquartered in Ivry-sur-Seine, France.
CAC 40 ended the session with FORSEE POWER falling 6.37% to €2.35 on Monday, following the last session’s downward trend. CAC 40 rose 0.55% to €7,689.80, following the last session’s downward trend on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, FORSEE POWER has a trailing twelve months EPS of €-0.61.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -58.61%.
Yearly Top and Bottom Value
FORSEE POWER’s stock is valued at €2.35 at 21:40 EST, under its 52-week low of €2.56.
Volume
Today’s last reported volume for FORSEE POWER is 51499 which is 157.76% above its average volume of 19979.
Moving Average
FORSEE POWER’s value is way below its 50-day moving average of €3.02 and way below its 200-day moving average of €3.08.
Revenue Growth
Year-on-year quarterly revenue growth grew by 58.4%, now sitting on 140.05M for the twelve trailing months.
More news about FORSEE POWER.
4. CELYAD ONCOLOGY (CYAD.BR)
-5.85% Price Change
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
BEL 20 ended the session with CELYAD ONCOLOGY sliding 5.85% to €0.37 on Monday, after two sequential sessions in a row of gains. BEL 20 jumped 1.07% to €3,715.85, after three sequential sessions in a row of gains, on what was an all-around bullish trend exchanging session today.
Earnings Per Share
As for profitability, CELYAD ONCOLOGY has a trailing twelve months EPS of €-1.36.
Volume
Today’s last reported volume for CELYAD ONCOLOGY is 19947 which is 59.75% below its average volume of 49562.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CELYAD ONCOLOGY’s stock is considered to be oversold (<=20).
Volatility
CELYAD ONCOLOGY’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.46%, a positive 0.50%, and a positive 3.41%.
CELYAD ONCOLOGY’s highest amplitude of average volatility was 2.16% (last week), 2.95% (last month), and 3.41% (last quarter).
More news about CELYAD ONCOLOGY.
5. VAA VISTA ALEGRE (VAF.LS)
-5.73% Price Change
Vista Alegre Atlantis, SGPS, S.A. produces, distributes, and sells porcelain tableware, decorative and giftware; tableware, barware, decanters, candlesticks/tea lights, glass sets, and desk accessories. It also provides stainless steel cutlery products. In addition, the company offers lighting products. It provides its products through independent retailers, distributors, online as well as through its own retail network under the Vista Alegre brand name. Vista Alegre Atlantis, SGPS, S.A. was founded in 1980 and is headquartered in Ílhavo, Portugal. Vista Alegre Atlantis, SGPS, S.A. is a subsidiary of Visabeira Indústria SGPS, S.A.
PSI ended the session with VAA VISTA ALEGRE sliding 5.73% to €0.91 on Monday while PSI rose 1.11% to €6,194.21.
Earnings Per Share
As for profitability, VAA VISTA ALEGRE has a trailing twelve months EPS of €279.03.
Volume
Today’s last reported volume for VAA VISTA ALEGRE is 3729 which is 86.9% below its average volume of 28479.
More news about VAA VISTA ALEGRE.
6. KEYWARE TECH. (KEYW.BR)
-5.05% Price Change
Keyware Technologies NV, an independent fintech company, provides electronic payment solutions in Belgium. It offers payment transaction software for banks and financial institutions, tokenization software, instalment payment solutions, and ordering and payment app software; and payment processing and management services, as well as rents and sells payment terminals. The company was incorporated in 1996 and is headquartered in Zaventem, Belgium.
BEL 20 ended the session with KEYWARE TECH. falling 5.05% to €0.94 on Monday, after two consecutive sessions in a row of losses. BEL 20 rose 1.07% to €3,715.85, after three consecutive sessions in a row of gains, on what was an all-around positive trend exchanging session today.
Earnings Per Share
As for profitability, KEYWARE TECH. has a trailing twelve months EPS of €0.05.
PE Ratio
KEYWARE TECH. has a trailing twelve months price to earnings ratio of 18.8. Meaning, the purchaser of the share is investing €18.8 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.71%.
Volume
Today’s last reported volume for KEYWARE TECH. is 3016 which is 20.27% below its average volume of 3783.
Volatility
KEYWARE TECH.’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.34%, a positive 0.54%, and a positive 2.73%.
KEYWARE TECH.’s highest amplitude of average volatility was 1.01% (last week), 2.37% (last month), and 2.73% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, KEYWARE TECH.’s stock is considered to be overbought (>=80).
More news about KEYWARE TECH..
7. AKVA GROUP (AKVA.OL)
-5.02% Price Change
AKVA group ASA designs, purchases, manufactures, assembles, sells, and installs technology products; and provides rental and consulting services for the aquaculture industry. The company operates through three segments: Sea Based Technology (SBT), Digital, and Land Based Technology. The SBT segment offers plastic cages, steel cages, fish farming cages, feed barges, feed systems, sensor and camera systems, light systems, net cleaning systems, remotely operating vehicles, and nets and mooring systems under the Polarcirkel, Wavemaster, and Akvasmart hardware brands. This segment also supplies polyethylene boats and pipes to aquaculture and other industries, as well as plastic pen. The Digital segment provides production control, planning, traceability, and ERP software for the aquaculture and fishing industries under the Fishtalk, AKVAconnect, and AKVA Observe. The Land Based Technology segment designs and delivers recirculation systems for land-based fish farming, as well as provides water quality conditions for fresh and seawater operations. AKVA group ASA operates in Norway, Chile, the United Kingdom, Denmark, Canada, and internationally. The company was incorporated in 1982 and is based in Klepp Stasjon, Norway. AKVA group ASA is a subsidiary of Egersund Group AS.
Oslo Børs Benchmark Index_GI ended the session with AKVA GROUP sliding 5.02% to €49.20 on Monday while Oslo Børs Benchmark Index_GI jumped 0.84% to €1,250.87.
Earnings Per Share
As for profitability, AKVA GROUP has a trailing twelve months EPS of kr-0.54.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -8.75%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AKVA GROUP’s stock is considered to be overbought (>=80).
More news about AKVA GROUP.
8. HOFSETH BIOCARE (HBC.OL)
-4.96% Price Change
Hofseth BioCare ASA operates as a consumer and pet health ingredient supplier in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol, joint, eye, brain, and cardiovascular function; ProGo, a salmon protein hydrolysate powder for treatment of irondeficiency anaemia, irritable bowel syndrome, and sarcopenia; CalGo, a marine calcium powder produced to support cartilage function, joint health, and bone strength; CollaGo; and PetGo, a non-soluble protein. Hofseth BioCare ASA was incorporated in 2009 and is headquartered in Ålesund, Norway.
Oslo Børs Benchmark Index_GI ended the session with HOFSETH BIOCARE falling 4.96% to €2.30 on Monday, after three consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI rose 0.84% to €1,250.87, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.
Earnings Per Share
As for profitability, HOFSETH BIOCARE has a trailing twelve months EPS of kr-0.24.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -66.44%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 65.1%, now sitting on 204.7M for the twelve trailing months.
Volume
Today’s last reported volume for HOFSETH BIOCARE is 101241 which is 43.9% above its average volume of 70352.
More news about HOFSETH BIOCARE.
9. TELEVERBIER (TVRB.PA)
-4.39% Price Change
Téléverbier SA engages in the operation of ski lifts in Switzerland. The company is involved in the car parks and locker activities; rental of operating buildings and building surfaces; operation of ski schools; and sale and rental of sporting goods; operation of restaurants, as well as offers catering services. It also operates garage workshop and spare parts store for the maintenance of piste groomers; and metal construction workshop, as well as provides maintenance services for ski lift installations. Téléverbier SA was incorporated in 1950 and is headquartered in Verbier, Switzerland.
CAC 40 ended the session with TELEVERBIER dropping 4.39% to €54.50 on Monday while CAC 40 rose 0.55% to €7,689.80.
Earnings Per Share
As for profitability, TELEVERBIER has a trailing twelve months EPS of €8.26.
PE Ratio
TELEVERBIER has a trailing twelve months price to earnings ratio of 6.6. Meaning, the purchaser of the share is investing €6.6 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.42%.
Moving Average
TELEVERBIER’s worth is way higher than its 50-day moving average of €46.00 and way above its 200-day moving average of €44.80.
More news about TELEVERBIER.
10. HYBRID SOFTWARE GR (HYSG.BR)
-4.27% Price Change
Hybrid Software Group PLC, together with its subsidiaries, develops software and hardware technology solutions for graphics and industrial inkjet printing in the United Kingdom, rest of Europe, North and South America, and Asia. The company offers Harlequin Core, a raster image processor (RIP) software that converts text and image data from various file formats, including PDF, TIFF, and JPEG files; ScreenPro, a software that converts tone image data into ready-to-print halftone in real-time; and Mako SDK, a software that creates, rasterizes, converts, analyses, and optimizes various page description languages, as well as allows print software developers to control over colour, fonts, text, images, vector content, and metadata. It also provides Harlequin Direct, a software that drives print data directly to the printer electronics instead of buffering them on mass storage devices; SmartDFE, a turnkey digital front end based on Harlequin Direct, CLOUDFLOW, and Meteor for digital printing of labels and packaging; Navigator Harlequin RIP and Workflow, a software that offers prepress environments to interpretation of PostScript, PDF, and EPS format files; Navigator DFE, a software that helps to prepare jobs, manage colour, and control digital output devices built with Memjet or any standard inkjet printhead; and Output Device Interfaces, a hardware and software solutions to connect RIPs to computer-to-plate devices, imagesetters, proofers, digital presses, high-speed copiers, and inkjet printers. The company was formerly known as Global Graphics PLC and changed its name to Hybrid Software Group PLC in October 2021. Hybrid Software Group PLC was founded in 1986 and is headquartered in Cambridge, the United Kingdom.
BEL 20 ended the session with HYBRID SOFTWARE GR dropping 4.27% to €3.14 on Monday while BEL 20 jumped 1.07% to €3,715.85.
Earnings Per Share
As for profitability, HYBRID SOFTWARE GR has a trailing twelve months EPS of €0.02.
PE Ratio
HYBRID SOFTWARE GR has a trailing twelve months price to earnings ratio of 157. Meaning, the purchaser of the share is investing €157 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.54%.
More news about HYBRID SOFTWARE GR.
Stay up to date with our winners and losers daily report
